Entopsis explores the use of its novel diagnostic platform, OpsisDxTM, for the detection of COVID-19
Monday, March 30, 2020
Entopsis explores the use of its novel diagnostic platform, OpsisDxTM, for the detection of COVID-19 and triage of at-risk patients
March 30, 2020
MIAMI, FLA. – A unique non-DNA / RNA-based diagnostic approach may help diagnose
people with COVID-19 with greater accuracy than currently available and at a low cost. In
addition, this approach may identify people who are most likely to require hospitalization early in the course of the infection; thus allowing healthcare personal to focus attention on these most at-risk people.
Entopsis’ diagnostic platform, OpsisDxTM, relies on ‘molecular profiles’ combined with machine learning to categorize or diagnose people. These molecular profiles are created by unbiasedly sampling molecules from a person’s urine and then using these profiles to train a machine learning algorithm to discern between people positive and negative for the condition of interest.
Entopsis will apply its OpsisDxTM technology for the diagnosis of COVID-19 and the triage of people most likely to require hospitalization.
OpsisDxTM has already been successful at distinguishing between patients with 5 common
cancers and hepatitis B viral infection (manuscript submitted). To date, this platform has been particularly capable at detecting early stage cancers better than liquid biopsies.
Entopsis is backed by Peter Thiel’s Breakout Labs with the aim of developing a low-cost, highly flexible, multi-disease diagnostic platform.
“Our team is undoubtedly taking an unconventional technological approach to diagnostics.
However, if we are ultimately successful in our mission, we stand to revolutionize the detection of disease and health states”, Obdulio Piloto Ph.D., Entopsis CEO and co-founder.